<DOC>
	<DOCNO>NCT00095199</DOCNO>
	<brief_summary>This trial multicenter , open-label , randomize , Phase III study patient recurrent progressive Non-Small Cell Lung Cancer ( NSCLC ) failure initial platinum-based chemotherapy . Patients receive either Docetaxel Pemetrexed chemotherapy investigator 's choice . Within chemotherapy group , patient randomize receive Cetuximab plus chemotherapy chemotherapy alone ( Cetuximab &amp; Pemetrexed Pemetrexed alone ; Cetuximab &amp; Docetaxel Docetaxel alone ) .</brief_summary>
	<brief_title>Docetaxel Pemetrexed With Without Cetuximab Patients With Recurrent Progressive Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologic confirmation metastatic , unresectable , locallyadvanced NSCLC . Disease progression follow one prior platinumbased chemotherapy regimen advance disease ( stage IIIB IV ) . Bidimensionally measurable disease . Karnofsky performance status score 60 100 study entry . The participant tumor tissue available immunohistochemical determination epidermal growth factor ( EGFR ) expression . Adequate recovery recent surgery , chemotherapy , radiation therapy . At least 4 week must elapse major surgery , prior chemotherapy , prior treatment investigational agent , prior radiation therapy ( palliative radiation therapy allow ) . Accessible treatment followup . Participants enrol trial must treat participate center . Women childbearing potential ( WOCBP ) fertile men partner childbearing potential must use adequate method contraception . WOCBP must negative serum urine pregnancy test . Women pregnant breastfeeding . Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent . A serious uncontrolled medical disorder would impair ability patient receive protocol therapy . Symptomatic uncontrolled metastasis brain . Participants receive glucocorticoid brain metastasis exclude , receive anticonvulsant eligible . Uncontrolled pleural effusion ascites . Peripheral neuropathy great grade 2 , assess National Cancer InstitutesCommon Toxicity Criteria Adverse Events ( NCICTCAE ) , Version 3.0 . Any concurrent malignancy basal cell skin cancer , carcinoma situ cervix . Patients previous malignancy , without evidence disease great equal 3 year allow enter trial . More one prior chemotherapy regimen advance disease . Inadequate hematologic function define absolute neutrophil count ( ANC ) &lt; 1,500/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin level &lt; 9 g/dL . Red blood cell transfusion permit within 7 day receive cetuximab , docetaxel , pemetrexed . Inadequate hepatic function , define total bilirubin level &gt; 1.5 time upper limit normal ( ULN ) , aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) level &gt; 2.5 time ULN ( great equal 5 time ULN know liver metastasis ) , alkaline phosphatase level &gt; 5.0 time ULN . Inadequate renal function define serum creatinine level &gt; 1.5 time ULN . Prior treatment cetuximab , epidermal growth factor receptor inhibitor , include tyrosine kinase inhibitor , gefitinib erlotinib . Participants must receive prior chimerized murine monoclonal antibody therapy . Prior treatment monoclonal antibody target receptor EGFR permit &gt; 30 day prior randomization . Prior treatment docetaxel pemetrexed therapy . Inability unwillingness take folic acid vitamin B12 supplementation . Inability unwillingness interrupt nonsteroidal antiinflammatory drug ( NSAIDs ) 5day period ( 8day period longacting agent piroxicam ) . Aspirin permit study . Patients ( include prisoner ) compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( eg , infectious disease ) illness . Prior treatment experimental drug medical device within 30 day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Recurrent Progressive Non-Small Cell Lung Cancer</keyword>
	<keyword>Second-line therapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Failed platinum-based therapy</keyword>
	<keyword>NSCLC</keyword>
</DOC>